Coenzyme Q 10: A Vital Therapeutic Nutrient for the Heart with Special Application in Congestive Heart Failure

Connecticut Medicine

Volumn 61, Issue 11, 1997, Pages 707-711

  Sinatra, Stephen T ^a,b  

^a Manchester Dental Hospital   (United Kingdom)

^b UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; UBIDECARENONE; DRUG DERIVATIVE; UBIQUINONE;

AGED; ARTICLE; CASE REPORT; CONGESTIVE HEART FAILURE; DIASTOLE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEART EJECTION FRACTION; HUMAN; MALE; QUALITY OF LIFE; SYSTOLE; ENZYMOLOGY; HEART MUSCLE; METABOLISM; MORTALITY; SURVIVAL RATE;

AGED; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MYOCARDIUM; QUALITY OF LIFE; SURVIVAL RATE; UBIQUINONE;

EID: 0030609114     PISSN: 00106178     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Frishman WH, Greenberg SM, Goldschmidt M, et al: Innovative pharmacologic approaches for the treatment of my ocardial ischemia, In: Frishman WH, Sonnenblick EH, eds. Cardiovascular Pharmacotherapeutics. New York, New York: McGraw-Hill; 1997:846-50.
2. 10: A new drug for cardiovascular disease. Clin Pharm. 1990; 30:596-608.
3. Stocker R, Bowry VW, Frei B: Ubiquinol-10 protects human low density lipoproteins more efficiently against lipid peroxidation than does a-tocopherol. Proc Natl Acad Sci USA. 1991; 88: 1646-50.
4. 10 supplementation alters platelet size and inhibits human vitronectin (CD51/CD61) receptor expression. J Cardiovas Pharm. 1997; 29:16-22.
5. Kishi T, Okamoto T, Kishi H, Okada A: Serum levels of coenzyme Q10 in patients receiving total parenteral nutrition and relationship of serum lipids. In: Folkers K, Yamamura Y, (eds). Biomedical and Clinical Aspects of Coenzyme Q. Amsterdam: Elsevier; 1986; 5:119.
6. 10 in human heart disease. Int J Vitam Nutr Res. 1972; 42:291-305.
7. 10 determination. J Endocrinol Invest. 1989; 12:511-6.
8. 10 on exercise tolerance in chronic stable angina pectoris. Am J Cardiol. 1985; 56:247-51.
9. 10 on essential arterial hypertension. Cur Ther Res 1990; 47:841-5.
10. 10 and respiratory chain enzyme activities in hypertrophied human left ventricles with aortic valve stenosis. Am J Cardiol. 1990; 66:504-5.
11. 10 as an adjunctive in treatment of congestive heart failure. Am J Cardiol 1992; Supplement 19(3),216A.
12. 10 therapy in patients with congestive heart failure: A long-term multicenter randomized study. In: Folkers K, Mortensen SA, Littarru GP, et al (eds): Seventh International Symposium on biomedial and Clinical Aspects of Coenzyme Q. The Clinical Investigator, 1993; 71:S134-S36.
13. 10 therapy for idiopathic dilated cardiomyopathy. Am J Cardiol. 1990; 65:512-23.
14. 10 from myocardial reperfusion injury during coronary artery bypass grafting. Ann Thorac Surg 1994; 58:1427-32.
15. 10 of patients in heart failure who are eligible or ineligible for a transplant. Biochem Biophys Res Commun. 1992; 182:247-53.
16. 10. Mol Aspects Med 1994; 15:8287-5294.
17. 10 treatment. Clin Invest 1993;71:S140-4.
18. 10. Mol Aspects Med 1997; in Press.
19. 10 in the cell: Some biochemical and physiological properties. Physiol Res 1995; 44:209-16.
20. 10-lowering effect by HMG-CoA-reductase inhibitors: A double-blind, placebo-controlled study. J Clin Pharm 1993; 33:226-9